Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 15;66(5):487-94.
doi: 10.1097/QAI.0000000000000201.

Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011)

Richard Kaplan  1 , Judy Caldwell, Keren Middelkoop, Linda-Gail Bekker, Robin Wood
Affiliations

Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011)

Richard Kaplan et al. J Acquir Immune Defic Syndr. .

Abstract

Objective: To identify determinants of tuberculosis (TB) case fatality including the impact of antiretroviral therapy (ART) at different CD4 thresholds for HIV-positive adult and adolescent TB patients.

Methods: Through a retrospective analysis of the electronic TB database, we identified the HIV status of newly registered patients aged ≥15 years. Multivariable Cox proportional hazard models were used to determine the risk factors for TB case fatality in these patients.

Results: In 2009, 2010, and 2011, 25,841, 26,104, and 25,554 newly registered adult TB patients were treated in primary health care clinics in Cape Town, of whom 49.7%, 50.4%, and 50.9% were HIV positive. ART uptake increased over 3 years from 43% to 64.9%, and case fatality of the HIV-positive patients decreased from 7.0% to 5.8% (P < 0.001). Female gender, increasing age, retreatment TB, low CD4 counts, and extrapulmonary TB were associated with increased case fatality, whereas patients on ART had a substantial decrease in case fatality. The difference in case fatality between patients on ART and not on ART was most pronounced at low CD4 counts with the positive influence of ART noted up to a CD4 count threshold of 350 cells per cubic millimeter (P < 0.001). Despite improvements in ART uptake, in 2011, 21% of the patients with CD4 counts <350 cells per cubic millimeter did not start ART during TB treatment.

Conclusion: This study showed a relatively poor uptake of ART among severely immune-compromised TB patients. Patients with CD4 counts <350 cells per cubic millimeter were shown to clearly benefit from ART during TB treatment, and ART initiation should be prioritized for this category of patients.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts of interest.

Figures

Figure 1
Figure 1
ART uptake and TB case fatality stratified by CD4 count for HIV-positive patients with baseline CD4 counts over the 3 year period (n=37,163) (a) ART uptake stratified by CD4 count (b) TB case fatality stratified by CD4 count and ART status. TB=Tuberculosis; Dx=Diagnosis; Rx=Treatment
Figure 1
Figure 1
ART uptake and TB case fatality stratified by CD4 count for HIV-positive patients with baseline CD4 counts over the 3 year period (n=37,163) (a) ART uptake stratified by CD4 count (b) TB case fatality stratified by CD4 count and ART status. TB=Tuberculosis; Dx=Diagnosis; Rx=Treatment
Figure 2
Figure 2
Kaplan-Meier plots showing survival and retention in care for the HIV-positive patients. (a) Survival by ART status for HIV-positive patients with CD4 <350 cells/mm3. (b) Survival by CD4 count for HIV-positive patients. (c) Retention in care by ART status for HIV-positive patients. (d) Retention in care by CD4 count for HIV-positive patients.
Figure 2
Figure 2
Kaplan-Meier plots showing survival and retention in care for the HIV-positive patients. (a) Survival by ART status for HIV-positive patients with CD4 <350 cells/mm3. (b) Survival by CD4 count for HIV-positive patients. (c) Retention in care by ART status for HIV-positive patients. (d) Retention in care by CD4 count for HIV-positive patients.
Figure 2
Figure 2
Kaplan-Meier plots showing survival and retention in care for the HIV-positive patients. (a) Survival by ART status for HIV-positive patients with CD4 <350 cells/mm3. (b) Survival by CD4 count for HIV-positive patients. (c) Retention in care by ART status for HIV-positive patients. (d) Retention in care by CD4 count for HIV-positive patients.
Figure 2
Figure 2
Kaplan-Meier plots showing survival and retention in care for the HIV-positive patients. (a) Survival by ART status for HIV-positive patients with CD4 <350 cells/mm3. (b) Survival by CD4 count for HIV-positive patients. (c) Retention in care by ART status for HIV-positive patients. (d) Retention in care by CD4 count for HIV-positive patients.
See this image and copyright information in PMC

References

    1. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143–152. - PubMed
    1. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–1491. - PMC - PubMed
    1. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–1481. - PMC - PubMed
    1. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697–706. - PMC - PubMed
    1. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Available at http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. - PubMed

Publication types

MeSH terms